SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

LGVN

Longeveron
BEARISH
Impact 6/10
Horizonweeks Processed3d 18h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The strategic review process (potential sale/merger) is the primary catalyst. Monitor for any definitive agreement or financing announcement. The failed HLHS trial and limited cash runway increase the likelihood of a dilutive financing or distressed sale.

DirectionBearish
Confidencehigh
Horizonweeks

laromestrocel

▼ Bearish Named in this press release
Impact
Phase
Phase 2
Time to market
Not stated
Next catalyst
None dated

What to watchThe next near-term event is the AHA 2026 Scientific Sessions podium presentation of the ELPIS II secondary endpoint data (date TBD). A positive reception could provide a short-term bounce, but the primary endpoint failure already limits the HLHS regulatory path. The bigger binary is the outcome of the strategic alternatives review, a sale or partnership could unlock value, while failure to find a deal could force a dilutive financing or a wind-down. Watch for 8-K filings for any 8-K regarding a potential sale, financing or Nasdaq compliance notice.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$2.49
T+0 close · Nov 12, 2026 · via day close
Latest settled
−14.06%
T+1 · $2.14
Vs SPY
−12.14%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $2.49entry
  2. T+1 · 20h ago −14.06%α −12.14% · $2.14
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Longeveron reported Q3 2026 net loss of $6.1M ($1.91 per share) on revenue of $0.1M, missing the consensus EPS estimate of -$1.70. The ELPIS II Phase 2b trial for HLHS failed its primary endpoint, and the company has initiated a strategic review process with Lucid Capital Markets, exploring a potential sale or merger. Cash stands at $7.2M, expected to fund operations into Q1 2027.

Key Financial Metrics

EPS
−$1.91
est −$1.70 · -12.3%
Revenue
$115.0K
est $800.0K · -85.6% · -16.0% YoY
Rating
miss

Key Facts

  • Q3 2026 net loss of $6.1M, or $1.91 per share, on revenue of $0.1M
  • EPS of -$1.91 missed consensus of -$1.70 (surprise -12.4%)
  • Revenue declined 16% YoY to $0.1M, in line with consensus of $0.8M? (consensus $800K appears to be annualized or misaligned; actual quarterly revenue $115K)
  • ELPIS II Phase 2b trial for HLHS failed primary endpoint (RVEF at Month 12)
  • Company initiated strategic review, retained Lucid Capital Markets for potential sale/merger
  • Cash and cash equivalents of $7.2M as of Sep 30, 2026, expected to fund operations into Q1 2027
  • No conference call held due to strategic review process
  • 1-for-10 reverse stock split effective August 26, 2026

Financial Impact

Net loss of $6.1M on $0.1M revenue; cash runway into Q1 2027; EPS miss of $0.21 vs consensus

revenueepscash

Risk Factors

  • ELPIS II trial failure may impair HLHS program viability and FDA path
  • Cash only into Q1 2027; substantial doubt about going concern without financing or deal
  • Strategic review may not result in favorable terms or any transaction
  • Nasdaq continued listing risk given sub-$1M market cap

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402293

Track record

22 reports on LGVN

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
  2. Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
  3. Nov 12, 20264d ago 8-K Bearish 7/10 No price data
  4. Nov 12, 20264d ago Press Release Bearish 6/10 Viewing Entry $2.49 Now $2.14 +14.06% settles Feb 11
  5. Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
  6. Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
  7. Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
  8. Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
  9. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
  10. Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026